Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 9, 2013, Pages 1211-1220

  Lee, Y T ^a   Tsao, S M ^a   Hsueh, P R ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AGED; ANALYTICAL EQUIPMENT; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; MALE; MINOCYCLINE; PIPERACILLIN; SULBACTAM; TREATMENT OUTCOME;

EID: 84882585192     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1870-4     Document Type: Article

References (52)

1. Gignon M, Farcy S, Schmit JL, Ganry O (2012) Prevention of healthcare-associated infections in general practice: current practice and drivers for change in a French study. Indian J Med Microbiol 30:69-75
2. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, Ko WC (2007) Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 28:713-719 (Pubitemid 46954759)
3. Salgado CD, O'Grady N, Farr BM (2005) Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit Care Med 33:2373-2382 (Pubitemid 41437495)
4. Brusselaers N, Vogelaers D, Blot S (2011) The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 1:47
5. Fournier PE, Richet H (2006) The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42:692-699 (Pubitemid 43271386)
6. Gordon NC, Wareham DW (2009) A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63:775-780
7. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A (2007) Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13:97-103 (Pubitemid 46057843)
8. Maragakis LL, Perl TM (2008) Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46:1254-1263 (Pubitemid 351589912)
9. Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-260, second page, table of contents (Pubitemid 32538179)
10. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41:S341-S353 (Pubitemid 41170381)
11. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group (2005) A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 5:88 (Pubitemid 41582039)
12. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST) Group (2005) In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 52:173-179 (Pubitemid 41133542)
13. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL (2007) Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59(1):128-131 (Pubitemid 46017915)
14. Peleg AY, Hooper DC (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362:1804-1813
15. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group (2008) A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62:i29-i40
16. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62:895-904
17. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J (2007) Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35:1888-1895 (Pubitemid 47220363)
18. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME (2008) Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62:45-55 (Pubitemid 351865873)
19. Fishbain J, Peleg AY (2010) Treatment of Acinetobacter infections. Clin Infect Dis 51:79-84
20. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128-140
21. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-332 (Pubitemid 351763841)
22. Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 2(7872):81-84
23. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE (1981) APACHE - acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 9:591-597
24. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710
25. [No authors listed] (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874
26. Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582
27. Clinical and Laboratory Standards Institute (CLSI) (2006) Performance standards for antimicrobial disk susceptibility tests; Approved standard - 9th edition. CLSI document M2-A9,. CLSI, Wayne, PA
28. Clinical and Laboratory Standards Institute (CLSI) (2011) Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. CLSI document M100-S21. CLSI, Wayne, PA
29. Chen YH, Lu PL, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Liu JW, Sun W, Wang LS, Ko WC, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR (2012) Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006-2010. Antimicrob Agents Chemother 56:1452-1457
30. Dryden MS (2010) Complicated skin and soft tissue infection. J Antimicrob Chemother 65:iii35-iii44
31. Manchanda V, Sanchaita S, Singh N (2010) Multidrug resistant Acinetobacter. J Glob Infect Dis 2:291-304
32. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66:1963-1971
33. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C (2010) Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 10:287
34. Napolitano LM (2008) Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt) 9:s17-s27
35. Bhattacharya M, Parakh A, Narang M (2009) Tigecycline. J Postgrad Med 55:65-68
36. Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA (2011) Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39(6):515-518
37. Kuti JL, Dowzicky M, Nicolau DP (2008) A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. J Chemother 20:69-76 (Pubitemid 351428666)
38. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H; 311 Study Group (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68:140-151
39. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, Byun MK (2012) Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J 53:974-984
40. Prasad P, Sun J, Danner RL, Natanson C (2012) Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:1699-1709
41. Powers JH (2012) Editorial commentary: asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials. Clin Infect Dis 54:1710-1713
42. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851
43. Marchaim D, Navon-Venezia S, Schwartz D, Tarabeia J, Fefer I, Schwaber MJ, Carmeli Y (2007) Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol 45:1551-1555 (Pubitemid 46762412)
44. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, Llanos AC, Pachón J (2004) Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 48:4479-4481 (Pubitemid 39434923)
45. Rodríguez-Hernández M-J, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jiménez-Mejías ME, García-Curiel A, Pachón J (2001) Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 47:479-482 (Pubitemid 32303419)
46. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, Chuang YC (2004) In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 53:393-395 (Pubitemid 38239982)
47. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA (2002) Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34:1425-1430 (Pubitemid 34553700)
48. Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ (2011) Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother 66:1625-1630
49. Gallagher JC, Rouse HM (2008) Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 42:1188-1194
50. Lee CH, Tang YF, Su LH, Chien CC, Liu JW (2008) Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. Microb Drug Resist 14:233-237
51. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA (2007) Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484 (Pubitemid 47519332)
52. Dijkshoorn L, Brouwer CP, Bogaards SJ, Nemec A, van den Broek PJ, Nibbering PH (2004) The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48:4919-4921 (Pubitemid 39577708)